Medicine Clown Loop introduces the first personalized GLP-1 dosage platform in the USA

Close Loop Medicine Ltd (CLM), the leader of a personalized pharmaceutical dosage, has today announced an American launch according to Clinicists, which enables clinicians to personalize large-scale GLP-1.

The launch appears when the global anti-tongue market, worth over $ 30 billion in 2024, is reaching $ 100 billion until 2030. Despite this growth, GLP-1 therapies face a serious challenge in the real world: up to 44 % of patients to stop treatment within six months, and this number will increase to 60 % in 12 months. This significant decrease in adhesion is often caused by the dose of chairmanship of side effects such as nausea, vomiting and diarrhea, but also in a lack of support for how these drugs should be used in the long run and then maintain weight loss. Many patients are self -sufficient doses without medical supervision, based on anecdotal evidence, which completely limits the long -term success of treatment.

According to, he solves these challenges, presenting personalized dosage options for clinical inspection, based on tolerance, treatment goals and clinical data and adapting them in time based on the unit’s response to the drug. The platform enables healthcare providers, teeth companies and healthcare systems to make conscious primensions regarding titration using the best available evidence and keeping patients in effective therapy for longer.

91 % of surveyed patients from GLP-1 agreed or definitely agreed that they would be more willing to treat if they had support according to them.

The solution is based on 29 clinical studies and over 15,000 patients’ profiles, supported by advanced pharmacokinetic/pharmacodynamic modeling (PK/PD). In the study of hypertension, CLM dosage technology provided better treatment results, less side effects and exceptional compliance – achievements that are now used for GLP -1 therapy for the first time. Amarillo Premier Research, the Celivehealth site in Texas, starts using WOSIFA this week.

Dr with each, clinicist in Texas, commented on:

The launch is the main milestone for CLM, which introduces its first product available in trade for clinicians and patients in the US, is based on the diverse foundation of intellectual property and clinical data, because the company focuses on conducting more effective central care of patients.

According to the purposes of the act on the proper dose of the drug, it directly supports the purposes of drug producers and distributors to offer safer, more effective treatment methods through the precision of prescribing, reducing undesirable drug events. By improving drug therapeutic profiles, it enables premium valuation and unlocks new streams of income at a critical moment when US policy can seriously reduce pharmaceutical advertising directly to patients. The platform facilitates simulations in real time and reporting patients and clinicists, also contributing to the involvement of HTI-4 in the White House in the Ecosystem of Digital Health Care-oriented Patient Care, using digital tools for better results.